414 related articles for article (PubMed ID: 28470103)
1. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Hamed K; Debonnett L
Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
[TBL] [Abstract][Full Text] [Related]
2. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
5. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
McKeage K
Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
Panguluri S; Gunda P; Debonnett L; Hamed K
Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
[TBL] [Abstract][Full Text] [Related]
9. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
[TBL] [Abstract][Full Text] [Related]
10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
14. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
15. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
Harrison MJ; McCarthy M; Fleming C; Hickey C; Shortt C; Eustace JA; Murphy DM; Plant BJ
J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
[TBL] [Abstract][Full Text] [Related]
16. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
17. The use of tobramycin for Pseudomonas aeruginosa: a review.
Fiel SB; Roesch EA
Expert Rev Respir Med; 2022 May; 16(5):503-509. PubMed ID: 35320051
[TBL] [Abstract][Full Text] [Related]
18. Eradication of
Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
[TBL] [Abstract][Full Text] [Related]
19. Aerosolized antibiotics in cystic fibrosis: an update.
Fiel SB
Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
[TBL] [Abstract][Full Text] [Related]
20. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
Stuart Elborn J; Geller DE; Conrad D; Aaron SD; Smyth AR; Fischer R; Kerem E; Bell SC; Loutit JS; Dudley MN; Morgan EE; VanDevanter DR; Flume PA
J Cyst Fibros; 2015 Jul; 14(4):507-14. PubMed ID: 25592656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]